Sensorion Names GJB2 Hearing Loss Therapy as Lead Program; Ends OTOF Trial
Montpellier, France – June 11, 2026 – Sensorion, a pioneering biotechnology company focused on developing innovative therapies for inner ear diseases, has announced a significant strategic reorientation of its gene…
